News
Microdosing Research News
Monitored category — items publish only when newsworthy and sourced.
The research-news category tracks new GLP-1 microdosing and dose-response studies: trial registrations, publications, and their findings and limitations. We link the primary record — a DOI, PMID, or ClinicalTrials.gov identifier — and never report a result from a press release alone.
Category page indexable; items gated. An item appears here only with a primary source and an event date. We would rather show nothing than manufacture freshness.
What we watch in this category
- New dose-response and reduced-dose trials for semaglutide and tirzepatide
- Maintenance and withdrawal study publications
- Real-world cohorts on compounded products
- Registrations that have not yet reported
Primary sources monitored
Not medical advice. This page is consumer education, not medical advice, and does not recommend a dose, product, or provider. Compounded medications are not FDA approved. Talk with a licensed clinician about your situation.